Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis

EBioMedicine

Volumn 2, Issue 2, 2015, Pages 172-179

  Sloot, Rosa ^a   Schim van der Loeff, Maarten F ^a,b   van Zwet, Erik W ^c   Haks, Mariëlle C ^c   Keizer, Sytze T ^b   Scholing, Maarten ^b,d   Ottenhoff, Tom H M ^c   Borgdorff, Martien W ^a,b   Joosten, Simone A ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

DcRT MLPA; Gene expression; HIV; Host biomarkers; Tuberculosis

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; BIOLOGICAL MARKER; INTERFERON; INTERLEUKIN 13; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSTEOPONTIN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; VIRUS LOAD; WESTERN BLOTTING; ADDICTION; BLOOD; COMPLICATION; MIDDLE AGED; TUBERCULOSIS, PULMONARY;

ADULT; BIOMARKERS; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON TYPE I; INTERLEUKIN-13; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; TRANSCRIPTION FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84943234197     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2014.12.001     Document Type: Article

References (34)

1. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 289-300.
2. Berry M.P., Graham C.M., McNab F.W., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
3. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3):89-95.
4. Cliff J.M., Lee J.S., Constantinou N., et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect. Dis. 2013, 207:18-29.
5. Comstock G.W., Livesay V.T., Woolpert S.F. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 1974, 99:131-138.
6. Dakhama A., Collins M.L., Ohnishi H., et al. IL-13-producing BLT1-positive CD8 cells are increased in asthma and are associated with airway obstruction. Allergy 2013, 68:666-673.
7. Dorhoi A., Yeremeev V., Nouailles G., et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur. J. Immunol. 2014, (Epub ahead of print). 10.1002/eji.201344219.
8. + T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 2009, 60:1119-1128.
9. + T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum. 2013, 65:236-246.
10. Geluk A., van Meijgaarden K.E., Wilson L., et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J. Clin. Immunol. 2014, 34:245-255. 10.1007/s10875-013-9979-x.
11. Heitmann L., Abad Dar M., Schreiber T., et al. The IL-13/IL-4R-alpha axis is involved in tuberculosis-associated pathology. J. Pathol. 2014, 10.1002/path.4399.
12. Hijnen D., Knol E.F., Gent Y.Y., et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J. Investig. Dermatol. 2013, 133:973-979.
13. Joosten S.A., Goeman J.J., Sutherland J.S., et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immunol. 2012, 13:71-82.
14. Joosten S.A., Fletcher H.A., Ottenhoff T.H. A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS One 2013, 8:e73230.
15. Keizer S.T., Langendam M.M., van Deutekom H., Coutinho R.A., van Ameijden E.J. How does tuberculosis relate to HIV positive and HIV negative drug users?. J. Epidemiol. Community Health 2000, 54:64-68.
16. KNCV Tuberculosis Foundation Commissie voor Praktische Tuberculosebestrijding. Handboek TBC-bestrijding Nederland 2008, KNCV, The Hague.
17. Mack U., Migliori G.B., Sester M., et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 2009, 33:956-973.
18. Maertzdorf J., Ota M., Repsilber D., et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One 2011, 6:e26938.
19. Maertzdorf J., Repsilber D., Parida S.K., et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immunol. 2011, 12:15-22.
20. Maertzdorf J., Weiner J., Mollenkopf H.J., et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7853-7858.
21. Mayer-Barber K.D., Andrade B.B., Oland S.D., et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 3(511(7507)):99-103. (Epub 2014 Jun 25). 10.1038/nature13489.
22. + T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum. 2011, 63:1738-1747.
23. Nunn P., Williams B., Floyd K., Dye C., Elzinga G., Raviglione M. Tuberculosis control in the era of HIV. Nat. Rev. Immunol. 2005, 5(10):819-826.
24. Ottenhoff T.H., Ellner J.J., Kaufmann S.H. Ten challenges for TB biomarkers. Tuberculosis 2012, 92(Suppl. 1):S17-S20.
25. Ottenhoff T.H., Dass R.H., Yang N., et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 2012, 7:e45839.
26. + effector T cells but elevated levels of FoxP3+ regulatory t cells in the granulomatous lesions. Am. J. Pathol. 2009, 174:2211-2224.
27. Schuetz A., Haule A., Reither K., Ngwenyama N., et al. Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo. PLoS One 2011, 6(11):e27284. (Epub 2011 Nov 7). 10.1371/journal.pone.0027284.
28. Teles R.M., Graeber T.G., Krutzik S.R., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013, 22(339(6126)):1448-1453. (Epub 2013 Feb 28). 10.1126/science.1233665.
29. The GC#6-74 Consortium (accessed 27 August 2014). http://www.biomarkers-for-tb.net/consortium/the-consortium.
30. Tibshirani R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B Methodol. 1996, 267-288.
31. van den Hoek J.A., Coutinho R.A., van Haastrecht H.J., van Zadelhoff A.W., Goudsmit J. Prevalence and risk factors of HIV infections among drug-users and drug-using prostitutes in Amsterdam. AIDS 1988, 2:55-60.
32. Vynnycky E., Fine P.E. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 2000, 152:247-263.
33. Weiner J., Kaufmann S.H. Recent advances towards tuberculosis control: vaccines and biomarkers. J. Intern. Med. 2014, 275(5):467-480. 10.1111/joim.12212.
34. World Health Organization (WHO): Global Tuberculosis Report (accessed 13 August 2014). http://www.who.int/tb/publications/global_report/en/.